QL Biopharm’s Zovaglutide Offers Potentially Safer Once-Monthly Obesity Option

Phase III Program Now Planned

 
• By Dexter Jie Yan
  
QL Biopharm believes less frequent dosing may encourage obesity patients to stay longer on treatment (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D